Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07022964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

StatusRecruiting
PhasePhase 1/2
Started2025-06-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 1, 2026 → Nov 1, 2026
See other at-risk trials from Beijing GoBroad Hospital

Amendment history

2026-09-09
Study Identification, Study Status, Arms and Interventions, Outcome Measures v1
Primary completion pushed: 2026-06-01 → 2026-11-01
Secondary endpointsdetails revised at 1 of 2 entries
2025-06-08
Original filing
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Trial Details
NCT Number NCT07022964
Lead Sponsor Beijing GoBroad Hospital
Collaborators: Ruijin Hospital, Shanghai Liquan Hospital
Conditions T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
Enrollment 36 participants
Start Date 2025-06-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-11